NFE2L2 and amyotrophic lateral sclerosis: Within this expanded pathogenic framework, Nrf2 has emerged as a master regulatory node with the capacity to orchestrate protective transcriptional responses across multiple converging disease pathways, positioning it as a compelling therapeutic target in ALS [36,130].